Inhibiting ACAT2 may help eliminate heart disease
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Dr. Larry Rudel joins Dr. Larry Kaskel to discuss the enzyme ACAT2 and its confirmed relationship with LDL. Dr. Rudel's new study in mice raises a tantalizing possibility. By inhibiting ACAT2, will we one day be able to eat any kind of fat we want without raising our risk of heart disease?
Overview
Dr. Larry Rudel joins Dr. Larry Kaskel to discuss the enzyme ACAT2 and its confirmed relationship with LDL. Dr. Rudel's new study in mice raises a tantalizing possibility. By inhibiting ACAT2, will we one day be able to eat any kind of fat we want without raising our risk of heart disease?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Digital Therapeutics Clinical Trials: From Design to Data Interpretation
Engaging Patients and Caregivers About Digital Therapeutics
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
Optimizing PPD Diagnosis and Treatment: The Role of Neuroactive Steroids and Multidisciplinary Care
HF Management for Patients with Comorbid Conditions
Collaborative Insights to Solve the Puzzle of Bladder Cancer
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?